UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000024261
Receipt No. R000027843
Scientific Title Comprehensive analysis of iron and mineral-bone metabolism after HCV clearance by daclatasvir and asunaprevir combination therapy in genotype 1 HCV-infected hemodialysis patients
Date of disclosure of the study information 2016/10/03
Last modified on 2018/03/05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Comprehensive analysis of iron and mineral-bone metabolism after HCV clearance by daclatasvir and asunaprevir combination therapy in genotype 1 HCV-infected hemodialysis patients
Acronym Comprehensive analysis of iron and mineral-bone metabolism after HCV clearance by daclatasvir and asunaprevir combination therapy in genotype 1 HCV-infected hemodialysis patients
Scientific Title Comprehensive analysis of iron and mineral-bone metabolism after HCV clearance by daclatasvir and asunaprevir combination therapy in genotype 1 HCV-infected hemodialysis patients
Scientific Title:Acronym Comprehensive analysis of iron and mineral-bone metabolism after HCV clearance by daclatasvir and asunaprevir combination therapy in genotype 1 HCV-infected hemodialysis patients
Region
Japan

Condition
Condition genotype 1 HCV patients receiving hemodialysis
Classification by specialty
Hepato-biliary-pancreatic medicine
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 we aim at examining the effect on iron and mineral-bone metabolism after HCV clearance by daclatasvir and asunaprevir combination therapy in genotype 1 HCV-infected hemodialysis patients
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes To compare erythropoietic resistance index change between pre and post of treatment in the early intervention group and waiting intervention group
Key secondary outcomes To assess Iron metabolism kinetics
To assess mineral-bone metabolism kinetics
To assess antiviral activity, the proportion of subjects who achieve undetectable HCV RNA at post treatment week 12
To assess safety
To assess CLDQ-HCV, KDQOL-SF

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control No treatment
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment Central registration

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 The subjects will be randomly assigned to the early intervention group and waiting intervention group. After entry in the study, the early intervention group will orally receive ASV 100 mg per dose twice daily and DCV 60 mg once daily for 24 weeks. After this treatment, the subjects will be observed for a further 24 week period.
Interventions/Control_2 The waiting intervention group will wait for the first 24 weeks and then receive the ASV/DCV combination therapy.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1)20 years old or older
2)Genotype 1 HCV -infected patients receiving hemodialysis
3)Patients who were provided with sufficient explanation before participating in this study and who provided written consent to participate in this study on their own free will.
Key exclusion criteria 1)Patients with decompensated cirrhosis
2)Patients complicated with hepatic cancer
3)Other patients whom the chief investigator or a sub-investigators considers inappropriate

Target sample size 120

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yoshitaka Arase
Organization Tokai University School of Medicine
Division name Department of Gastroenterology and Hepatology
Zip code
Address shimokasuya 143, Isehara, Kanagawa, Japan
TEL 0463-93-1121
Email arase@tokai-u.jp

Public contact
Name of contact person
1st name
Middle name
Last name Yoshitaka Arase
Organization Tokai University Oiso Hospital
Division name Department of Gastroenterology and Hepatology
Zip code
Address Gakkyo 21-1, Oisotyo, Nakagun, Kanagawa, Japan
TEL 0463-72-3211
Homepage URL
Email arase@tokai-u.jp

Sponsor
Institute Department of Gastroenterology and Hepatology, Tokai University School of Medicine
Institute
Department

Funding Source
Organization Bristol-Myers Squibb
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 東海大学医学部付属病院
東海大学医学部付属大磯病院
東海大学医学部付属八王子病院
東海大学医学部付属東京病院
帝京大学医学部付属病院
順天堂大学医学部付属順天堂医院 
順天堂大学医学部付属練馬病院
医療法人社団 松和会 池上総合病院

Other administrative information
Date of disclosure of the study information
2016 Year 10 Month 03 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2016 Year 06 Month 29 Day
Date of IRB
Anticipated trial start date
2016 Year 10 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2016 Year 10 Month 03 Day
Last modified on
2018 Year 03 Month 05 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027843

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.